These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
74 related articles for article (PubMed ID: 29974233)
1. Lopinavir serum concentrations of critically ill infants: a pharmacokinetic investigation in South Africa. Schultheiß M; Kling S; Lenker U; von Bibra M; Rosenkranz B; Klinker H Med Microbiol Immunol; 2018 Nov; 207(5-6):339-343. PubMed ID: 29974233 [TBL] [Abstract][Full Text] [Related]
2. Are lopinavir and efavirenz serum concentrations in HIV-infected children in the therapeutic range in clinical practice? von Bibra M; Rosenkranz B; Pretorius E; Rabie H; Edson C; Lenker U; Cotton M; Klinker H Paediatr Int Child Health; 2014 May; 34(2):138-41. PubMed ID: 24225343 [TBL] [Abstract][Full Text] [Related]
3. [Pharmacokinetic profiles of lopinavir (LPV) in Chinese HIV-infected patients]. Zhang X; Liu Z; Du X; Fu Q; Li T Zhonghua Nei Ke Za Zhi; 2015 May; 54(5):431-3. PubMed ID: 26080823 [TBL] [Abstract][Full Text] [Related]
5. Plasma concentrations of the HIV-protease inhibitor lopinavir are suboptimal in children aged 2 years and below. Verweel G; Burger DM; Sheehan NL; Bergshoeff AS; Warris A; van der Knaap LC; Driessen G; de Groot R; Hartwig NG Antivir Ther; 2007; 12(4):453-8. PubMed ID: 17668553 [TBL] [Abstract][Full Text] [Related]
6. Lopinavir/ritonavir plus lamivudine and abacavir or zidovudine dose ratios for paediatric fixed-dose combinations. Bouazza N; Foissac F; Fauchet F; Burger D; Kiechel JR; Treluyer JM; Capparelli EV; Lallemant M; Urien S Antivir Ther; 2015; 20(2):225-33. PubMed ID: 25279808 [TBL] [Abstract][Full Text] [Related]
7. A hybrid design to optimize preparation of lopinavir loaded solid lipid nanoparticles and comparative pharmacokinetic evaluation with marketed lopinavir/ritonavir coformulation. Ravi PR; Vats R; Dalal V; Murthy AN J Pharm Pharmacol; 2014 Jul; 66(7):912-26. PubMed ID: 24697749 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic Interactions Between Quinine and Lopinavir/Ritonavir in Healthy Thai Adults. Rattanapunya S; Cressey TR; Rueangweerayut R; Tawon Y; Kongjam P; Na-Bangchang K Am J Trop Med Hyg; 2015 Dec; 93(6):1383-90. PubMed ID: 26416104 [TBL] [Abstract][Full Text] [Related]
9. Influence of SLCO1B1 polymorphisms on lopinavir C Dragović G; Dimitrijević B; Kušić J; Soldatović I; Jevtović D; Olagunju A; Owen A Br J Clin Pharmacol; 2020 Jul; 86(7):1289-1295. PubMed ID: 32022294 [TBL] [Abstract][Full Text] [Related]
10. [Lopinavir/ritonavir in patients with human immunodeficiency virus infection in special situations]. Tasias M; Aldeguer JL Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():18-21. PubMed ID: 25542871 [TBL] [Abstract][Full Text] [Related]
11. Reduced lopinavir exposure during pregnancy. Stek AM; Mirochnick M; Capparelli E; Best BM; Hu C; Burchett SK; Elgie C; Holland DT; Smith E; Tuomala R; Cotter A; Read JS AIDS; 2006 Oct; 20(15):1931-9. PubMed ID: 16988514 [TBL] [Abstract][Full Text] [Related]
12. [Positioning of lopinavir/ritonavir in antiretroviral treatment schemes]. Camacho Á; Rivero A Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():31-4. PubMed ID: 25542874 [TBL] [Abstract][Full Text] [Related]
13. Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz. Pham PA; Hendrix CW; Barditch-Crovo P; Parsons T; Khan W; Parish M; Radebaugh C; Carson KA; Pakes GE; Qaqish R; Flexner C Antivir Ther; 2007; 12(6):963-9. PubMed ID: 17926651 [TBL] [Abstract][Full Text] [Related]
14. Concentration-response model of lopinavir/ritonavir in HIV-1-infected pediatric patients. Bouazza N; Urien S; Blanche S; Hirt D; Foissac F; Benaboud S; Tréluyer JM; Frange P Pediatr Infect Dis J; 2014 Aug; 33(8):e213-8. PubMed ID: 24509655 [TBL] [Abstract][Full Text] [Related]
15. Are Prophylactic and Therapeutic Target Concentrations Different?: the Case of Lopinavir-Ritonavir or Lamivudine Administered to Infants for Prevention of Mother-to-Child HIV-1 Transmission during Breastfeeding. Foissac F; Blume J; Tréluyer JM; Tylleskär T; Kankasa C; Meda N; Tumwine JK; Singata-Madliki M; Harper K; Illamola SM; Bouazza N; Nagot N; Van de Perre P; Blanche S; Hirt D Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27895016 [TBL] [Abstract][Full Text] [Related]
16. Serum Vitamin D Status and Outcome among Critically Ill Children Admitted to the Pediatric Intensive Care Unit in South India. Ebenezer K; Job V; Antonisamy B; Dawodu A; Manivachagan MN; Steinhoff M Indian J Pediatr; 2016 Feb; 83(2):120-5. PubMed ID: 26187509 [TBL] [Abstract][Full Text] [Related]
17. Correlation between lopinavir plasma levels and lipid abnormalities in patients taking lopinavir/ritonavir. González de Requena D; Blanco F; Garcia-Benayas T; Jiménez-Nácher I; González-Lahoz J; Soriano V AIDS Patient Care STDS; 2003 Sep; 17(9):443-5. PubMed ID: 14588081 [TBL] [Abstract][Full Text] [Related]
18. HIV protease inhibitors disrupt astrocytic glutamate transporter function and neurobehavioral performance. Vivithanaporn P; Asahchop EL; Acharjee S; Baker GB; Power C AIDS; 2016 Feb; 30(4):543-52. PubMed ID: 26558720 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children. van der Lee M; Verweel G; de Groot R; Burger D Antivir Ther; 2006; 11(4):439-45. PubMed ID: 16856617 [TBL] [Abstract][Full Text] [Related]
20. Lopinavir and atazanavir in pregnancy: comparable infant outcomes, virological efficacies and preterm delivery rates. Perry ME; Taylor GP; Sabin CA; Conway K; Flanagan S; Dwyer E; Stevenson J; Mulka L; McKendry A; Williams E; Barbour A; Dermont S; Roedling S; Shah R; Anderson J; Rodgers M; Wood C; Sarner L; Hay P; Hawkins D; deRuiter A HIV Med; 2016 Jan; 17(1):28-35. PubMed ID: 26200570 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]